XML 24 R10.htm IDEA: XBRL DOCUMENT
v3.23.1

Note 2 - Revenue | 12 Months Ended
--- | ---
Mar. 31, 2023
Notes to Financial Statements |
Revenue from Contract with Customer [Text Block] | Note 2. Revenue We develop, manufacture, market, sell and maintain life sciences tools and quality control instruments and related software, consumables, and services. Hardware sales include physical products such as instruments used for molecular and genetic analysis, protein synthesizers, medical meters, wireless sensor systems, and data loggers. Hardware sales may be offered with accompanying perpetual or annual software licenses, which in some cases are required for the hardware to function. Consumables are typically used on a one-time basis and require frequent replacement in our customers' operating cycles. Consumables such as reagents used for molecular and genetic analysis or solutions used for protein synthesis are critical to the ongoing use of our instruments. Consumables such as biological indicator test strips are used on a standalone basis. We also offer maintenance, calibration, and testing service contracts. These contracts result in revenues recognized over time, for example, when we are obligated to perform labor and replace parts on an as-needed basis over a contractually specified period of time, or at a point in time, upon completion of a specific, discrete service. In many cases, our contracts contain both revenues recognized over time and revenues recognized at a point in time. We evaluate our revenues internally based on operating segment, the nature of goods and services provided, and the timing of revenue generation. The following tables present disaggregated revenues from contracts with customers for the years ended March 31, 2023, 2022 and 2021:
|  | Year Ended March 31, 2023 |
|  | Clinical Genomics (1) |  |  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Total |
Consumables |  | $ | 43,374 |  |  | $ | 55,605 |  |  | $ | 15,800 |  |  | $ | 3,062 |  |  | $ | 117,841 |
Hardware and Software |  |  | 13,347 |  |  |  | 692 |  |  |  | 22,079 |  |  |  | 26,561 |  |  |  | 62,679 |
Services |  |  | 5,578 |  |  |  | 8,312 |  |  |  | 9,486 |  |  |  | 15,184 |  |  |  | 38,560 |
Total Revenues |  | $ | 62,299 |  |  | $ | 64,609 |  |  | $ | 47,365 |  |  | $ | 44,807 |  |  | $ | 219,080 |
|  | Year Ended March 31, 2022 |
|  | Clinical Genomics (1) |  |  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Total |
Consumables |  | $ | 22,271 |  |  | $ | 50,311 |  |  | $ | 15,551 |  |  | $ | 3,675 |  |  | $ | 91,808 |
Hardware and Software |  |  | 6,726 |  |  |  | 700 |  |  |  | 21,651 |  |  |  | 28,537 |  |  |  | 57,614 |
Services |  |  | 3,843 |  |  |  | 8,033 |  |  |  | 8,377 |  |  |  | 14,660 |  |  |  | 34,913 |
Total Revenues |  | $ | 32,840 |  |  | $ | 59,044 |  |  | $ | 45,579 |  |  | $ | 46,872 |  |  | $ | 184,335 |
|  | Year Ended March 31, 2021 |
|  | Clinical Genomics (1) |  |  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Total |
Consumables |  | $ | - |  |  | $ | 45,869 |  |  | $ | 13,942 |  |  | $ | 3,198 |  |  | $ | 63,009 |
Hardware and Software |  |  | - |  |  |  | 505 |  |  |  | 13,545 |  |  |  | 29,969 |  |  |  | 44,019 |
Services |  |  | - |  |  |  | 6,745 |  |  |  | 6,405 |  |  |  | 13,759 |  |  |  | 26,909 |
Total Revenues |  | $ | - |  |  | $ | 53,119 |  |  | $ | 33,892 |  |  | $ | 46,926 |  |  | $ | 133,937 |
(1) Revenues in the Clinical Genomics division represent transactions subsequent to the acquisition of Agena Bioscience, Inc. on October 20, 2021. Contract Balances Our contracts have varying payment terms and conditions. Some customers prepay for products and services, resulting in either unearned revenues or customer deposits, called contract liabilities. Short-term contract liabilities are included within other accrued expenses and unearned revenues in the accompanying Consolidated Balance Sheets, and long-term contract liabilities are included within other long-term liabilities in the accompanying Consolidated Balance Sheets. The significant majority of our revenues and related receivables and contract liabilities are generated from contracts with customers with original expected durations of 12 months or less. Contract liabilities will be recognized to revenue as we satisfy our obligations under the terms of the contracts. A summary of contract liabilities is as follows:
Contract liabilities as of March 31, 2022 |  | $ | 15,069 |
Prior year liabilities recognized in revenues during the year ended March 31, 2023 |  |  | (8,643 | )
Contract liabilities added during the year ended March 31, 2023, net of revenues recognized |  |  | 9,672 |
Contract liabilities balance as of March 31, 2023 |  | $ | 16,098 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org//606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration